User login
A new AGA white paper, published in Clinical Gastroenterology and Hepatology, highlights barriers to care and calls for collaboration among our healthcare community, insurers, pharmaceutical companies, and legislators to improve and optimize care for more than 3 million Americans living with inflammatory bowel disease (IBD).
Over the last two decades, there has been a revolution in therapeutics fueled by exciting research and development that continues to expand the treatment options for IBD, offering tools for better disease control. However, the most effective therapies are cost prohibitive and have largely become inaccessible due to insurer-mandated barriers to care, such as prior authorization and step therapy.
AGA has created a plan that addresses these barriers and proposes tangible solutions to provide patients with high quality, high value care.
1. The lived experiences and valuable insights from both patients and expert clinicians should be reflected in the data and research represented in the field.
2. AGA recognizes the powerful benefit of individually tailoring IBD therapy based on risk, comorbidities and response, and encourages all stakeholders to do the same.
3. As a field, we need to move beyond insurer-mandated step therapy and fail first policies.
4. AGA urges insurers to cover all necessary disease activity and drug level monitoring, which will ensure patients are able to achieve treat-to-target-driven outcomes.
5. Streamlined and expedited expert reviews should be guaranteed to all providers when they are mandated by an insurer.
6. To ensure transparency and accountability, AGA wants to require that payors publish their denial and appeals data.
7. AGA believes that holistic patient-centered multidisciplinary care, including psychosocial and dietary support, should be covered by insurance. Having access to such care contributes to improved patient resilience and well-being, which will lead to decreased health care utilization and better health outcomes.
8. AGA supports the creation and continuation of a variety of patient education programs to improve health literacy and awareness of complex health care systems.
9. AGA is committed to improving patients’ access to expert specialized clinical IBD care. This includes flexible delivery models to ensure that underserved populations are being reached. In addition, AGA supports training and educating specialty providers across the spectrum of medical care (advanced practice providers, nurse educators, etc.) to increase the number of qualified IBD providers.
10. Piloting innovative shared incentive partnerships between high value subspecialty care practices and payors will be a new shared goal.
11. AGA wants to engage pharmaceutical partners in developing equitable programs to address prohibitive drug costs while also expanding patient access and support.
12. AGA plans to continue to advocate for legislation to make access to therapy equitable for Medicare and Medicaid patients.
“Unaffordable drug costs, step therapy, and other insurer-mandated barriers are fixable problems,” said M. Anthony Sofia, MD, a coauthor of the AGA white paper and an IBD specialist at Oregon Health and Science University, Portland.
“Every day, we see people that have been harmed by delayed and inadequate care. Solving these barriers would lift an unimaginable weight off our patient’s shoulders and allow them to lead healthier lives. We must work together to collaborate on solutions to strengthen and advance the care for all people with IBD.”
View the full white paper here.
A new AGA white paper, published in Clinical Gastroenterology and Hepatology, highlights barriers to care and calls for collaboration among our healthcare community, insurers, pharmaceutical companies, and legislators to improve and optimize care for more than 3 million Americans living with inflammatory bowel disease (IBD).
Over the last two decades, there has been a revolution in therapeutics fueled by exciting research and development that continues to expand the treatment options for IBD, offering tools for better disease control. However, the most effective therapies are cost prohibitive and have largely become inaccessible due to insurer-mandated barriers to care, such as prior authorization and step therapy.
AGA has created a plan that addresses these barriers and proposes tangible solutions to provide patients with high quality, high value care.
1. The lived experiences and valuable insights from both patients and expert clinicians should be reflected in the data and research represented in the field.
2. AGA recognizes the powerful benefit of individually tailoring IBD therapy based on risk, comorbidities and response, and encourages all stakeholders to do the same.
3. As a field, we need to move beyond insurer-mandated step therapy and fail first policies.
4. AGA urges insurers to cover all necessary disease activity and drug level monitoring, which will ensure patients are able to achieve treat-to-target-driven outcomes.
5. Streamlined and expedited expert reviews should be guaranteed to all providers when they are mandated by an insurer.
6. To ensure transparency and accountability, AGA wants to require that payors publish their denial and appeals data.
7. AGA believes that holistic patient-centered multidisciplinary care, including psychosocial and dietary support, should be covered by insurance. Having access to such care contributes to improved patient resilience and well-being, which will lead to decreased health care utilization and better health outcomes.
8. AGA supports the creation and continuation of a variety of patient education programs to improve health literacy and awareness of complex health care systems.
9. AGA is committed to improving patients’ access to expert specialized clinical IBD care. This includes flexible delivery models to ensure that underserved populations are being reached. In addition, AGA supports training and educating specialty providers across the spectrum of medical care (advanced practice providers, nurse educators, etc.) to increase the number of qualified IBD providers.
10. Piloting innovative shared incentive partnerships between high value subspecialty care practices and payors will be a new shared goal.
11. AGA wants to engage pharmaceutical partners in developing equitable programs to address prohibitive drug costs while also expanding patient access and support.
12. AGA plans to continue to advocate for legislation to make access to therapy equitable for Medicare and Medicaid patients.
“Unaffordable drug costs, step therapy, and other insurer-mandated barriers are fixable problems,” said M. Anthony Sofia, MD, a coauthor of the AGA white paper and an IBD specialist at Oregon Health and Science University, Portland.
“Every day, we see people that have been harmed by delayed and inadequate care. Solving these barriers would lift an unimaginable weight off our patient’s shoulders and allow them to lead healthier lives. We must work together to collaborate on solutions to strengthen and advance the care for all people with IBD.”
View the full white paper here.
A new AGA white paper, published in Clinical Gastroenterology and Hepatology, highlights barriers to care and calls for collaboration among our healthcare community, insurers, pharmaceutical companies, and legislators to improve and optimize care for more than 3 million Americans living with inflammatory bowel disease (IBD).
Over the last two decades, there has been a revolution in therapeutics fueled by exciting research and development that continues to expand the treatment options for IBD, offering tools for better disease control. However, the most effective therapies are cost prohibitive and have largely become inaccessible due to insurer-mandated barriers to care, such as prior authorization and step therapy.
AGA has created a plan that addresses these barriers and proposes tangible solutions to provide patients with high quality, high value care.
1. The lived experiences and valuable insights from both patients and expert clinicians should be reflected in the data and research represented in the field.
2. AGA recognizes the powerful benefit of individually tailoring IBD therapy based on risk, comorbidities and response, and encourages all stakeholders to do the same.
3. As a field, we need to move beyond insurer-mandated step therapy and fail first policies.
4. AGA urges insurers to cover all necessary disease activity and drug level monitoring, which will ensure patients are able to achieve treat-to-target-driven outcomes.
5. Streamlined and expedited expert reviews should be guaranteed to all providers when they are mandated by an insurer.
6. To ensure transparency and accountability, AGA wants to require that payors publish their denial and appeals data.
7. AGA believes that holistic patient-centered multidisciplinary care, including psychosocial and dietary support, should be covered by insurance. Having access to such care contributes to improved patient resilience and well-being, which will lead to decreased health care utilization and better health outcomes.
8. AGA supports the creation and continuation of a variety of patient education programs to improve health literacy and awareness of complex health care systems.
9. AGA is committed to improving patients’ access to expert specialized clinical IBD care. This includes flexible delivery models to ensure that underserved populations are being reached. In addition, AGA supports training and educating specialty providers across the spectrum of medical care (advanced practice providers, nurse educators, etc.) to increase the number of qualified IBD providers.
10. Piloting innovative shared incentive partnerships between high value subspecialty care practices and payors will be a new shared goal.
11. AGA wants to engage pharmaceutical partners in developing equitable programs to address prohibitive drug costs while also expanding patient access and support.
12. AGA plans to continue to advocate for legislation to make access to therapy equitable for Medicare and Medicaid patients.
“Unaffordable drug costs, step therapy, and other insurer-mandated barriers are fixable problems,” said M. Anthony Sofia, MD, a coauthor of the AGA white paper and an IBD specialist at Oregon Health and Science University, Portland.
“Every day, we see people that have been harmed by delayed and inadequate care. Solving these barriers would lift an unimaginable weight off our patient’s shoulders and allow them to lead healthier lives. We must work together to collaborate on solutions to strengthen and advance the care for all people with IBD.”
View the full white paper here.